Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
about
Anti-endotoxin vaccines: back to the futureUlinastatin and thymosin as immune modulators for the treatment of sepsisIntravenous immunoglobulin for treating sepsis, severe sepsis and septic shockUlinastatin and thymosin as immune modulators for the treatment of sepsisPassive immunity in prevention and treatment of infectious diseasesThe 21st International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 20-23 March 2001Pro/con clinical debate: are steroids useful in the management of patients with septic shock?Bench-to-bedside review: fulfilling promises of the Human Genome ProjectSepsis-induced myocardial dysfunction: pathophysiology and managementThe coagulopathy of acute sepsisAdvances in the management of sepsis and the understanding of key immunologic defectsReview of experimental animal models of biliary acute pancreatitis and recent advances in basic researchCell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cellsIs boosting the immune system in sepsis appropriate?Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKIReducing mortality in sepsis: new directionsTranscription factor NF kappa B expression and postsurgical organ dysfunctionalpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.An Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental DataSepsis: in search of cure.Surfactant therapy for acute lung injury and acute respiratory distress syndrome.Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism.Intravenous immunoglobulin for treating sepsis and septic shock.IL-6 adsorption dynamics in hemoadsorption beads studied using confocal laser scanning microscopyMyocardial dysfunction in sepsis: a large, unsolved puzzleImmunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages.Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studiesNovel HMGB1-inhibiting therapeutic agents for experimental sepsis.High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock.Impact of immunomodulating therapy on morbidity in patients with severe sepsis.Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis.Curcumin modulates leukocyte and platelet adhesion in murine sepsis.Anti-inflammatory therapies in sepsis and septic shock.Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in miceTherapies for sepsis. Emerging therapies for sepsis and septic shock
P2860
Q22305428-BBF7A8C0-1435-4865-BEF2-3C98DD8DF5F7Q24193380-76EC6452-9E00-4C52-9CE9-847AB0B900ECQ24198059-93F1114E-91B8-4564-BC12-51DADA34510DQ24202365-BBF513D1-037E-4294-9176-EE1C52550044Q24550699-AE16F535-7942-41E0-868C-878A0BEEFDA9Q24796106-65405977-90B1-41C4-96EC-6531AE4EAD32Q24796470-EDA27351-2068-40D8-9DB8-C8D5CDAAD1DEQ24798503-F52EDA4A-EB09-46F8-A023-C7FCDB0BC208Q26751572-EBE467DA-F52D-4EDC-BE41-799B82D27A0EQ26826950-6D87D63B-6C4F-47E2-8795-D3F6557AB0A2Q26865386-B7CE3EC4-6DFC-4059-B57E-6DF59DDC4CB5Q27001120-7B08AC4D-BCC7-4FE1-9E52-2A12D8F1EC09Q27026350-BBCF3309-9BB7-4C82-AD75-CD5209A9CD7CQ27691996-BCED5B94-28F9-427D-85E4-59BF072CFFDDQ27694575-8AF919B5-73AF-4F61-926A-C09F2961F350Q28195791-35A0ED41-9934-4639-8514-9C190D6ECCB8Q28345627-460550A4-5100-48E2-9091-AC0383F4653BQ28368431-410E5A0A-37E8-4802-8981-874CB30E6BB4Q30000073-0A3E17CC-982B-41E3-B62F-C43634FC8BA1Q30251753-85BC931B-E008-4B91-A06D-BB9776A6371CQ30426177-42223984-7576-4813-9FCD-0892B0573E9CQ30453726-FEE3B795-F273-4288-BD38-6655BC687E01Q30820719-44830AC3-2E96-4883-AEC1-620B4805FFD1Q30881468-706FC952-2B5C-4E04-8E84-4F06FDFCCDC0Q33353302-4D6174B6-8114-45DA-851F-FF74D93F2255Q33655250-2381731A-1E43-455E-83E2-A191DB0F6E82Q33750231-EE8C9EC9-393F-407E-8067-01AF02738ACCQ33751106-8D710B26-38B5-4527-B157-3EB842F2D478Q33764530-3C75ECA7-6C4D-4151-8AF9-A3F078656A62Q33767761-CC26CD5C-6677-4475-B1BF-9D2A0CE0C557Q33814903-1ADD0AA5-2700-4B28-9BB2-94A2ECA4B2BAQ33836853-7A65446A-BFFE-4D00-9784-3E903FD649ECQ33869944-EFC40EEA-CD5B-44BF-84FE-703E4B3E1206Q33872936-9055C0F8-2770-4C4D-BCA9-3A45D1889092Q33966333-3E95FFDF-0498-4541-B7B3-D3149DC86008Q34004912-B3101D3B-CC77-44E8-937A-578ECB557334Q34058712-0BF49433-FE1D-44F6-96F2-70AFE75BF0ACQ34074976-90153A82-D3A6-4CCA-8A42-183EE1BBB522Q34182992-F7827B58-A168-44FF-B4EE-71BFB7CB337FQ34185446-3A53E97B-668C-4DA9-BD49-9855ABDFA98A
P2860
Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@en
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@nl
type
label
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@en
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@nl
prefLabel
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@en
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@nl
P2093
P921
P1476
Efficacy and safety of monoclo ...... -alpha MAb Sepsis Study Group.
@en
P2093
H Silverman
R P Wenzel
S Nasraway
P304
P356
10.1001/JAMA.1995.03520360048038
P407
P577
1995-03-01T00:00:00Z